ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-PO115

Baclofen Toxicity in Patients with Impaired Kidney Function: A Review of Cases in the Literature

Session Information

  • Pharmacology
    October 24, 2024 | Location: Exhibit Hall, Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Pharmacology (PharmacoKinetics, -Dynamics, -Genomics)

  • 2000 Pharmacology (PharmacoKinetics, -Dynamics, -Genomics)

Authors

  • Rehman, Amna, Berkshire Medical Center, Pittsfield, Massachusetts, United States
  • Parada, Xavier F., Berkshire Medical Center, Pittsfield, Massachusetts, United States
Background

Baclofen is a gamma-aminobutyric acid derivative that inhibits presynaptic motor neurons, resulting in central anti spasticity. It is commonly used to treat muscle spasticity caused by central nervous system disorders. Baclofen neurotoxicity cases are usually iatrogenic but are poorly recognized resulting in significant health problems, mortality, and hospital resource utilization. Therefore, we present here a review of cases published in literature in regard to baclofen induced toxicity in patients with impaired renal function.

Methods

We searched pubmed database for key words: baclofen (adverse effects, poisoning, toxicity), chronic kidney failure, chronic renal insufficiency, end stage renal disease (Figure 1).

Results

We reviewed 12 published articles, with 16 patients of avg. CKD stage IV or V who received variable baclofen dose and developed neurotoxicity (Figure 2).

Conclusion

Our review emphasizes the association of baclofen use with adverse side effects in patients with chronic kidney disease including encephalopathy, dyskinesia, lethargy and tremors. The review highlights that as providers we need to recognize contraindications of baclofen use in patients with impaired renal function and consider other treatment options. Another important aspect is that there are currently no clear guidelines for dosing of baclofen in patients with decreased kidney function. Finally, the management of baclofen toxicity remains variable with no standard recommendations especially for patients with chronic kidney disease.